1 Min Read
Sept 5 (Reuters) - Global Blood Therapeutics Inc:
* Global Blood Therapeutics receives rare pediatric disease designation from FDA for GBT440 for treatment of sickle cell disease (scd) Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.